Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD ianalumab - BAFF-R inhibitor Study Indication Phase Patients Primary Outcome Measures NCT03217422 AMBER (CVAY736B2201) Autoimmune hepatitis Phase 2 80 Alanine aminotransferase (ALT) normalization Arms Intervention VAY736 Placebo control with conversion to active VAY736 Autoimmune hepatitis patients with incomplete response or intolerant to standard treatment of care Target Patients Read-out Milesstone(s) 2026 Publication TBD 79 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation